IMMUNOSCINTIGRAPHY USING 111INCYT103 PRIOR TO 2ND LOOK LAPAROTOMY IN OVARIAN-CANCER - A PILOT-STUDY

A prospective pilot study was performed in order to determine the effi cacy of In-111Cyt103 (ONCOScint(r) CR/OV) in the detection of the pres ence and location, or absence of disease among patients with epithelia l ovarian cancer who demonstrated no clinical or biochemical (Ca 125: <35 mu/ml) evidence of disease at the end of first-line therapy. Among 15 patients who underwent second-look laparotomy, the overall accurac y of the test was 60%. The test demonstrated a sensitivity of 62.5% an d a specificity of 57.1%. The predictive value of a positive test was 62.5% and of a negative test was 57. 1%. The correct location of disea se was predicted in 57% of patients with macroscopically appreciable t umors. ONCOScint(r) CR/OV offers little appreciable advantage over cur rent modalities in discriminating between the presence or absence of d isease among patients with epithelial ovarian cancer who demonstrate n o clinical evidence of disease at the end of first-line therapy.